143.91
-4.53 (-3.05%)
| Previous Close | 148.44 |
| Open | 149.33 |
| Volume | 3,302,588 |
| Avg. Volume (3M) | 1,763,395 |
| Market Cap | 25,373,493,248 |
| Price / Earnings (TTM) | 19.24 |
| Price / Earnings (Forward) | 12.22 |
| Price / Sales | 1.73 |
| Price / Book | 4.23 |
| 52 Weeks Range | |
| Earnings Date | 30 Apr 2025 - 5 May 2025 |
| Profit Margin | 8.91% |
| Operating Margin (TTM) | 15.97% |
| Diluted EPS (TTM) | 7.50 |
| Quarterly Revenue Growth (YOY) | 2.30% |
| Quarterly Earnings Growth (YOY) | -6.80% |
| Total Debt/Equity (MRQ) | 238.73% |
| Current Ratio (MRQ) | 0.840 |
| Operating Cash Flow (TTM) | 2.72 B |
| Levered Free Cash Flow (TTM) | 1.84 B |
| Return on Assets (TTM) | 5.32% |
| Return on Equity (TTM) | 22.55% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bearish | Bearish |
| Diagnostics & Research (Global) | Bearish | Bearish | |
| Stock | IQVIA Holdings, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.0 |
| Average | 1.63 |
|
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The research and development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The technology and analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Mid Core |
| % Held by Insiders | 0.88% |
| % Held by Institutions | 95.84% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 232.00 (JP Morgan, 61.21%) | Buy |
| Median | 187.50 (30.29%) | |
| Low | 160.00 (HSBC, 11.18%) | Hold |
| Average | 189.88 (31.94%) | |
| Total | 4 Buy, 4 Hold | |
| Avg. Price @ Call | 160.78 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Mizuho | 15 May 2025 | 190.00 (32.03%) | Buy | 156.13 |
| 09 Apr 2025 | 210.00 (45.92%) | Buy | 157.02 | |
| Baird | 07 May 2025 | 161.00 (11.88%) | Hold | 153.30 |
| Barclays | 07 May 2025 | 165.00 (14.65%) | Hold | 153.30 |
| 10 Apr 2025 | 170.00 (18.13%) | Hold | 143.22 | |
| UBS | 07 May 2025 | 185.00 (28.55%) | Buy | 153.30 |
| HSBC | 25 Apr 2025 | 160.00 (11.18%) | Hold | 150.28 |
| Truist Securities | 10 Apr 2025 | 216.00 (50.09%) | Buy | 143.22 |
| Citigroup | 04 Mar 2025 | 210.00 (45.92%) | Hold | 183.57 |
| JP Morgan | 18 Feb 2025 | 232.00 (61.21%) | Buy | 193.15 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |